# Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

> **NCT03835949** · PHASE1 · UNKNOWN · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Solid Tumor
- Metastatic Cancer

## Interventions

- **DRUG:** TJ004309
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03835949
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-16
- **Primary completion:** 2022-06
- **Final completion:** 2022-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835949, "Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03835949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*